Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 15;27(1):114.
doi: 10.1007/s11886-025-02248-1.

Autoimmune Pericarditis: Diagnosis and New Therapeutics

Heba Wassif  1 , Elizabeth Ghandakly  2 , Habib Layoun  2 , Jaideep Singh Bhalla  2 , Emily Littlejohn  3 , Tom Kai Ming Wang  4 , Elaine Husni  3 , Allan Klein  4
Affiliations
Review

Autoimmune Pericarditis: Diagnosis and New Therapeutics

Heba Wassif et al. Curr Cardiol Rep. .

Abstract

Purpose of review: To provide an overview of the diagnosis and updated therapeutic approach to autoimmune pericarditis.

Recent findings: Subtypes of autoimmune pericarditis may benefit from IL-1 inhibition and future phenotyping based on clinical presentation, biomarkers, and imaging may aid in guiding future therapeutic approaches. Autoimmune pericarditis is a unique phenotype of pericarditis for which there is scarce data. The clinical spectrum of pericardial involvement associated with autoimmune disorders varies in acuity, recurrence, severity, and symptomatic presentation. There is a pathophysiologic distinction that separates autoimmune and autoinflammatory pericarditis from other pericarditis presentations. This review explores the state of the art in diagnosis and therapeutic management.

Keywords: Autoimmune pericarditis; Autoinflammatory; Pericarditis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human and Animal Rights and Informed Consent: No animal or human subjects by the authors were used in this study. Competing Interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Pathophysiology for autoimmune pericarditis. The asterisk (*) signifies the mutation which is also shown on the Act1 receptor with the little orange piece. Act1: Act1 adaptor protein, essential intermediate for IL-17; C3: complement component 3; IFN: interferon; IL: interleukin; TNF: tumor necrosis factor; TRAF3IP2: TRAF3 interacting protein 2
Fig. 2
Fig. 2
Pericarditis presentation and diagnosis
See this image and copyright information in PMC

References

    1. Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;400(10354):733–43. - PubMed
    1. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European society of cardiology (ESC)Endorsed by: the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2015;36(42):2921–64. - PMC - PubMed
    1. Thompson GE, Bourne MH Jr., Casal Moura M, Baqir M, Cartin-Ceba R, Makol A, et al. Pleuritis and pericarditis in antineutrophil cytoplasmic Autoantibody-Associated vasculitis. Chest. 2021;160(2):572–81. - PubMed
    1. Kontzias A, Barkhodari A, Yao Q. Pericarditis in systemic rheumatologic diseases. Curr Cardiol Rep. 2020;22(11):142. - PubMed
    1. Luis SA, LeWinter MM, Magestro M, DerSarkissian M, Duh MS, Chang R, et al. Estimating the US pericarditis prevalence using National health encounter surveillance databases. Curr Med Res Opin. 2022;38(8):1385–9. - PubMed